We recently published a list of Top 8 Trending AI News Updates Investors Should Not Miss. In this article, we are going to take a look at where Myriad Genetics, Inc. (NASDAQ:MYGN) stands against other top trending AI news updates investors should not miss.
As AI takes over industries worldwide, the technology has begun replacing the redundant human workforce, as popular banks reveal plans to shrink headcount amid rapid AI adoption. The lightning-fast takeover of AI is also reflected in OpenAI’s claims that it now serves 400 million weekly active users, a 100 million jump in users since December 2024.
Scale AI CEO and founder Alexander Wang said at the Web Summit Qatar 2025 that the US and China are leading in AI preparedness.
“Nearly every country in the world, or nearly every company in the world, will ultimately likely build AI technology on top of either the US technology stack or that of the Chinese technology stack,” Wang noted.
Elsewhere, the surging demand for AI infrastructure has prompted South Korea to build the world’s biggest AI data center with a 3 GW capacity by 2028. The $10 billion project is expected to commence construction in H2 2025 and generate revenues of $2.5 billion annually.
“This is more than just a technological milestone; it’s a strategic leap forward for Korea’s global technological leadership. We are incredibly proud to partner with Stock Farm Road and the Jeollanam-do government to build this crucial infrastructure, creating an unprecedented opportunity to build the foundation for next-generation AI.”
-said SFR co-founder Dr Amin Badr-El-Din
We selected AI stocks by reviewing news articles, stock analysis, and press releases. We listed the stocks in ascending order of their hedge fund sentiment taken from Insider Monkey’s database of over 1000 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A medical professional in a laboratory analyzing the outcomes of a molecular diagnostic test.
Myriad Genetics, Inc. (NASDAQ:MYGN)
Number of Hedge Fund Holders: 21
Myriad Genetics, Inc. (NASDAQ:MYGN) develops precision medicine and molecular diagnostic testing solutions to perceive how genes affect diseases, help physicians evaluate associated risks, and guide treatment decisions to uplift patient outcomes at lower costs.
On February 24th, the company announced executing an agreement with PATHOMIQ Inc. to license the PATHOMIQ_PRAD AI tech platform, which will help doctors make well-informed pre- and post-surgery medical decisions for prostate cancer. PATHOMIQ Inc. innovates AI-powered prognostic and predictive tests to improve access to personalized medicine.
“Along with our Prolaris® Prostate Cancer Prognostic Test, we are pleased to leverage PATHOMIQ’s prognostic and predictive capabilities across different phases of the patient journey in prostate cancer. Having both genetic and morphologic insights at the time of biopsy combined with the enhanced ability to predict disease recurrence after initial therapy can lead to more informed treatment decisions and enhance the potential for better patient outcomes. This partnership is the latest step in the strategic expansion of Myriad’s oncology portfolio. Our molecular science expertise, combined with the latest in machine learning and AI, will uniquely position Myriad to deliver higher-quality insights for patients and clinicians in the fight against cancer.”
-said George Daneker, Jr., President and Chief Clinical Officer of Oncology at Myriad Genetics Inc.
Overall, MYGN ranks 5th on our list of top trending AI news updates investors should not miss. While we acknowledge the potential of MYGN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than MYGN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.
